U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06838520) titled 'Effect of ADT and ARPI on Bone Loss of Patients with Prostate Cancer' on Feb. 03.
Brief Summary: This study aims to assess the impact of Androgen Deprivation Therapy (ADT) and Androgen Receptor Pathway Inhibitors (ARPI) on bone quality in patients with prostate cancer. Patients undergoing ADT for prostate cancer often experience adverse effects such as decreased bone density and increased fracture risk. While ARPIs are emerging as novel therapeutic agents, their effects on bone quality remain unclear. This study will compare patients receiving combined ADT and ARPI therapy with those receiving ADT alone, evaluating changes in bone d...